Cargando…
Paediatrics: how to manage infantile haemangioma
Infantile haemangiomas (IHs) are relatively common benign vascular tumours found in the paediatric population. They have varying sizes and involve different depths in the skin leading to various colours, shapes and textures. Although considered harmless in most cases, they may lead to life-threateni...
Autores principales: | , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioExcel Publishing Ltd
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8029639/ https://www.ncbi.nlm.nih.gov/pubmed/33889196 http://dx.doi.org/10.7573/dic.2020-12-6 |
_version_ | 1783676047033630720 |
---|---|
author | Kim, Jason HS Lam, Joseph M |
author_facet | Kim, Jason HS Lam, Joseph M |
author_sort | Kim, Jason HS |
collection | PubMed |
description | Infantile haemangiomas (IHs) are relatively common benign vascular tumours found in the paediatric population. They have varying sizes and involve different depths in the skin leading to various colours, shapes and textures. Although considered harmless in most cases, they may lead to life-threatening complications or cause permanent disfigurations and organ dysfunction. For problematic IHs, the treatment options include oral and topical beta-blockers, systemic corticosteroids, laser treatment, and surgery. In this narrative review, the treatment options for problematic IH are compared and delivered concisely to facilitate the clinical decisions from practitioners, including those in primary care settings. Oral propranolol is currently considered the first-line intervention for problematic IHs. For superficial lesions, there is robust evidence for the use of topical timolol maleate. Systemic corticosteroids are sometimes used in specific situations such as resistance or contraindications to beta-blockers. Surgical excision can be considered in cases requiring urgent intervention such as airway obstruction; this can be done alongside laser therapies for the removal of residual tissue or when reconstructing areas of deformity. The combination of multiple treatment modalities may lead to a more rapid clinical response. |
format | Online Article Text |
id | pubmed-8029639 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | BioExcel Publishing Ltd |
record_format | MEDLINE/PubMed |
spelling | pubmed-80296392021-04-21 Paediatrics: how to manage infantile haemangioma Kim, Jason HS Lam, Joseph M Drugs Context Review Infantile haemangiomas (IHs) are relatively common benign vascular tumours found in the paediatric population. They have varying sizes and involve different depths in the skin leading to various colours, shapes and textures. Although considered harmless in most cases, they may lead to life-threatening complications or cause permanent disfigurations and organ dysfunction. For problematic IHs, the treatment options include oral and topical beta-blockers, systemic corticosteroids, laser treatment, and surgery. In this narrative review, the treatment options for problematic IH are compared and delivered concisely to facilitate the clinical decisions from practitioners, including those in primary care settings. Oral propranolol is currently considered the first-line intervention for problematic IHs. For superficial lesions, there is robust evidence for the use of topical timolol maleate. Systemic corticosteroids are sometimes used in specific situations such as resistance or contraindications to beta-blockers. Surgical excision can be considered in cases requiring urgent intervention such as airway obstruction; this can be done alongside laser therapies for the removal of residual tissue or when reconstructing areas of deformity. The combination of multiple treatment modalities may lead to a more rapid clinical response. BioExcel Publishing Ltd 2021-04-06 /pmc/articles/PMC8029639/ /pubmed/33889196 http://dx.doi.org/10.7573/dic.2020-12-6 Text en Copyright © 2021 Kim JHS, Lam JM https://creativecommons.org/licenses/by-nc-nd/4.0/Published by Drugs in Context under Creative Commons License Deed CC BY NC ND 4.0 which allows anyone to copy, distribute, and transmit the article provided it is properly attributed in the manner specified below. No commercial use without permission. |
spellingShingle | Review Kim, Jason HS Lam, Joseph M Paediatrics: how to manage infantile haemangioma |
title | Paediatrics: how to manage infantile haemangioma |
title_full | Paediatrics: how to manage infantile haemangioma |
title_fullStr | Paediatrics: how to manage infantile haemangioma |
title_full_unstemmed | Paediatrics: how to manage infantile haemangioma |
title_short | Paediatrics: how to manage infantile haemangioma |
title_sort | paediatrics: how to manage infantile haemangioma |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8029639/ https://www.ncbi.nlm.nih.gov/pubmed/33889196 http://dx.doi.org/10.7573/dic.2020-12-6 |
work_keys_str_mv | AT kimjasonhs paediatricshowtomanageinfantilehaemangioma AT lamjosephm paediatricshowtomanageinfantilehaemangioma |